Vivus Delays Annual Meeting on Eve of Board Proxy Vote

Vivus Inc., the drugmaker battling its largest shareholder for board control, pushed its annual meeting back three days while claiming the dissident investor made misleading statements about a proxy adviser recommendation.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.